David W. Fry

Inhibition of the epidermal growth factor receptor family of tyrosine kinases as an approach to cancer chemotherapy: progression from reversible to irreversible inhibitors.

D. W. Fry, David W. Fry, 1999 .

Tyrosine kinase inhibitors. 18. 6-Substituted 4-anilinoquinazolines and 4-anilinopyrido[3,4-d]pyrimidines as soluble, irreversible inhibitors of the epidermal growth factor receptor.

J. Smaill, W A Denny, J M Nelson, 2001, Journal of medicinal chemistry.

Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor.

W. Denny, A. Doherty, A. Bridges, 1998, Proceedings of the National Academy of Sciences of the United States of America.

Tyrosine kinase inhibitors. 19. 6-Alkynamides of 4-anilinoquinazolines and 4-anilinopyrido[3,4-d]pyrimidines as irreversible inhibitors of the erbB family of tyrosine kinase receptors.

P. Ellis, W. Denny, A. Bridges, 2006, Journal of medicinal chemistry.

Tyrosine kinase inhibitors. 5. Synthesis and structure-activity relationships for 4-[(phenylmethyl)amino]- and 4-(phenylamino)quinazolines as potent adenosine 5'-triphosphate binding site inhibitors of the tyrosine kinase domain of the epidermal growth factor receptor.

W. Denny, G. Rewcastle, A. Bridges, 1995, Journal of medicinal chemistry.

A specific inhibitor of the epidermal growth factor receptor tyrosine kinase.

A. Bridges, D. W. Fry, A. McMichael, 1994, Science.

Tyrosine kinase inhibitors. 15. 4-(Phenylamino)quinazoline and 4-(phenylamino)pyrido[d]pyrimidine acrylamides as irreversible inhibitors of the ATP binding site of the epidermal growth factor receptor.

W. Denny, G. Rewcastle, A. Bridges, 1999, Journal of medicinal chemistry.

Tyrosine kinase inhibitors. 8. An unusually steep structure-activity relationship for analogues of 4-(3-bromoanilino)-6,7-dimethoxyquinazoline (PD 153035), a potent inhibitor of the epidermal growth factor receptor.

W. Denny, G. Rewcastle, A. Bridges, 1996, Journal of medicinal chemistry.

Site-directed irreversible inhibitors of the erbB family of receptor tyrosine kinases as novel chemotherapeutic agents for cancer.

D. W. Fry, David W. Fry, 2000, Anti-cancer drug design.

Biochemical and antiproliferative properties of 4-[ar(alk)ylamino]pyridopyrimidines, a new chemical class of potent and specific epidermal growth factor receptor tyrosine kinase inhibitor.

W. Denny, G. Rewcastle, A. Bridges, 1997, Biochemical pharmacology.